As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

John P. Clancy, MD

Professor; Director of Pulmonary Medicine Research; Gunnar Esiason/Cincinnati Bell Chair, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Disclosures

Disclosure: John P. Clancy, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Concert Pharmaceuticals, Inc.; Gilead Sciences, Inc.; Nivalis Therapeutics; Vertex Pharmaceuticals Incorporated
Served as a speaker or a member of a speakers bureau for: Genentech, Inc.
Received grants for clinical research from: Gilead Sciences, Inc.; Nivalis Therapeutics; ProQR Therapeutics; Vertex Pharmaceuticals Incorporated

Dr Clancy does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Clancy does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty

Debbie S. Benitez, RN, MSN, ACNP-BC

Adult Nurse Practitioner/ Coordinator, Center for Cystic Fibrosis, Keck Medicine of USC, Los Angeles, California

Disclosures

Disclosure: Debbie S. Benitez, RN, MSN, ACNP-BC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech, Inc.; Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated
Served as a speaker or a member of a speakers bureau for: Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated

Dr Benitez does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Benitez does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Elliott C. Dasenbrook, MD, MHS

Director, Cleveland Clinic Adult Cystic Fibrosis Center, Cleveland Clinic Respiratory Institute Cleveland, Ohio

Disclosures

Disclosure: Elliott C. Dasenbrook, MD, MHS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead Sciences, Inc.; Savara Inc.; Vertex Pharmaceuticals Incorporated

Dr Dasenbrook does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Dasenbrook does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Christopher H. Goss, MD, MSc

Professor of Medicine and Pediatrics, Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington

Disclosures

Disclosure: Christopher H. Goss, MD, MSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.
Received grants for clinical research from: Vertex Pharmaceuticals IncorporatedGrant review for: Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated

Dr Goss does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Goss does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Julia Muino, MA

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Julia Muino, MA, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

Advances in Cystic Fibrosis: Perspectives From Orlando, 2016

Authors: John P. Clancy, MD; Elliott C. Dasenbrook, MD, MHS; Christopher H. Goss, MD, MSc; Debbie S. Benitez, RN, MSN, ACNP-BC
CME / ABIM MOC / CE Released: 11/28/2016
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/28/2017

Start Activity

Target Audience and Goal Statement

This activity is intended for pulmonologists, pediatricians, and gastroenterologists who care for patients who have cystic fibrosis.

The goal of this activity is to provide clinical perspective on recent data related to cystic fibrosis management.

Upon completion of this activity, participants will:

Have increased knowledge regarding emerging data on advances in CF pathophysiology and treatment
Have increased knowledge of best practices for the management of pulmonary and nonpulmonary symptoms

Disclosures

Moderator

John P. Clancy, MD

Professor; Director of Pulmonary Medicine Research; Gunnar Esiason/Cincinnati Bell Chair, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Disclosures

Disclosure: John P. Clancy, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Concert Pharmaceuticals, Inc.; Gilead Sciences, Inc.; Nivalis Therapeutics; Vertex Pharmaceuticals Incorporated
Served as a speaker or a member of a speakers bureau for: Genentech, Inc.
Received grants for clinical research from: Gilead Sciences, Inc.; Nivalis Therapeutics; ProQR Therapeutics; Vertex Pharmaceuticals Incorporated

Dr Clancy does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Clancy does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty

Debbie S. Benitez, RN, MSN, ACNP-BC

Adult Nurse Practitioner/ Coordinator, Center for Cystic Fibrosis, Keck Medicine of USC, Los Angeles, California

Disclosures

Disclosure: Debbie S. Benitez, RN, MSN, ACNP-BC, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Genentech, Inc.; Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated
Served as a speaker or a member of a speakers bureau for: Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated

Dr Benitez does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Benitez does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Elliott C. Dasenbrook, MD, MHS

Director, Cleveland Clinic Adult Cystic Fibrosis Center, Cleveland Clinic Respiratory Institute Cleveland, Ohio

Disclosures

Disclosure: Elliott C. Dasenbrook, MD, MHS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead Sciences, Inc.; Savara Inc.; Vertex Pharmaceuticals Incorporated

Dr Dasenbrook does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Dasenbrook does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Christopher H. Goss, MD, MSc

Professor of Medicine and Pediatrics, Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington

Disclosures

Disclosure: Christopher H. Goss, MD, MSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.
Received grants for clinical research from: Vertex Pharmaceuticals IncorporatedGrant review for: Gilead Sciences, Inc.; Vertex Pharmaceuticals Incorporated

Dr Goss does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Goss does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Julia Muino, MA

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Julia Muino, MA, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Pulmonary Medicine

CME / ABIM MOC / CE

Advances in Cystic Fibrosis: Perspectives From Orlando, 2016

Authors: John P. Clancy, MD; Elliott C. Dasenbrook, MD, MHS; Christopher H. Goss, MD, MSc; Debbie S. Benitez, RN, MSN, ACNP-BCFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 11/28/2016

Valid for credit through: 11/28/2017

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Section 1. Update on Inhaled Antibiotics

How will these findings influence your practice?
Elliott C. Dasenbrook, MD, MHS

Section 2. CFTR Modulators in Young Children

A summary of key results on mutation-targeting therapies in young children
Christopher H. Goss, MD, MSc

Section 3. Patient Education in Preventing Infection

What information do patients need to be effective partners in care?
Debbie S. Benitez, RN, MSN, ACNP-BC

Page 1 of 4

Update on Inhaled Antibiotics

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

John P. Clancy, MD

Faculty

Debbie S. Benitez, RN, MSN, ACNP-BC

Elliott C. Dasenbrook, MD, MHS

Christopher H. Goss, MD, MSc

Editor

Julia Muino, MA

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

CME / ABIM MOC / CE

Advances in Cystic Fibrosis: Perspectives From Orlando, 2016

Target Audience and Goal Statement

Disclosures

Moderator

John P. Clancy, MD

Faculty

Debbie S. Benitez, RN, MSN, ACNP-BC

Elliott C. Dasenbrook, MD, MHS

Christopher H. Goss, MD, MSc

Editor

Julia Muino, MA

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Advances in Cystic Fibrosis: Perspectives From Orlando, 2016

Contents of This CME Activity

Section 1. Update on Inhaled Antibiotics

Section 2. CFTR Modulators in Young Children

Section 3. Patient Education in Preventing Infection